Accuray Inc (ARAY) Stock Price, Quote & News

Company Profile

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tu...

Industry: Medical Devices

Sector: Healthcare

Phone: 608 824 2800

Fax: 608 824 2996

Website: www.accuray.com

Address:

1240 Deming Way, Madison, United States

CaesarZane Sep. 12 at 10:03 AM

$ARAY $HWM $TSLA 👈 Robotics is next!🚀🚀🚀 Full Analysis: https://youtu.be/7a0cvKonwqs

0 · Reply

Tokenist Sep. 8 at 4:37 PM

🤖🩺 The next medical revolution is here: AI + robots in surgery. LLMs are diagnosing better than doctors, and surgical robots are set to turn hospitals into high-tech operating rooms. The global robotics surgery market is forecast to hit $7.4B by 2030 🚀. 3 stocks on the cutting edge: $ARAY – Penny stock w/ CyberKnife S7 F radiosurgery tech + 264% upside potential. $SMMNY – Siemens Healthineers, AI-powered imaging + robotics, backlog tripled since IPO. $ISRG – The king of surgical robots w/ 10K+ da Vinci systems installed + AI-driven precision tools. Healthcare disruption is accelerating. Are you betting on the scalpel of the future? ⚡

1 · Reply

DCRMIA Sep. 5 at 5:00 PM

$ARAY Super bullish🚀📈

0 · Reply

d_risk Aug. 28 at 8:25 PM

$ARAY - Accuray Incorporated Common Stock - 10K - Updated Risk Factors ARAY’s 2025 10-K risk factors shift to stress financial health—highlighting substantial debt, covenant risks, and reliance on product sales—while expanding on supplier dependency, regulatory hurdles, China tariff impacts, geopolitical volatility, and operational complexities; several prior risks (indebtedness, manufacturing, product liability, growth management) were removed or narrowed. #FinancialHealth #GeopoliticalVolatility #RegulatoryChallenges #SupplierDependency #DebtRisk 🟢 Added 🟠 Removed https://d-risk.ai/ARAY/10-K/2025-08-28

0 · Reply

MGeronimo Aug. 27 at 6:08 PM

$ARAY accumulating at 1.59

0 · Reply

MSUalum Aug. 26 at 2:32 PM

$ARAY lol can't believe after all that BTIG puts a buy and raises the PT to 5. WTH are these guys on? They got a bit of a raw deal on financing, and based on the guidance all of their earnings are going to the banks, plus they can't grow revs or build backlog fast enough. I will probably throw in the towel on any next move up in all honesty.

0 · Reply

OptimistPrime7 Aug. 24 at 1:27 AM

$ARAY One day!

0 · Reply

BreakoutCrafter Aug. 23 at 5:53 AM

$ARAY Accuray Inc is a radiation oncology company facing competitive pressure and slow growth

0 · Reply

StockScanners Aug. 19 at 12:19 AM

$ARAY keep watch if this holds above 1.57

0 · Reply

OkieDokieTrader Aug. 18 at 11:00 PM

$ARAY When they sleep, we eat..? Ok I’m still working on something cool to say. Buy or cry, it’s up to you. Go check my receipts. I call out bangers damn near every day.

0 · Reply

Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025

Aug 13, 2025, 7:14 PM EDT - 4 weeks ago

Accuray Incorporated (ARAY) Q4 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 4 weeks ago

Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

Accuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025

Jun 6, 2025, 7:30 AM EDT - 3 months ago

Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

May 29, 2025, 7:30 PM EDT - 3 months ago

Accuray to Participate in the Jefferies Global Healthcare Conference 2025

May 7, 2025, 7:35 AM EDT - 4 months ago

Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

May 5, 2025, 4:10 PM EDT - 4 months ago

Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

May 3, 2025, 2:52 AM EDT - 4 months ago

Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade)

Apr 30, 2025, 10:38 PM EDT - 4 months ago

Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Accuray Reports Fiscal 2025 Third Quarter Financial Results

Apr 3, 2025, 7:35 AM EDT - 5 months ago

Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Mar 12, 2025, 7:30 AM EDT - 6 months ago

Accuray to Participate at 37th Annual Roth Conference

Feb 5, 2025, 10:03 PM EST - 7 months ago

Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 4:05 PM EST - 7 months ago

Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

Jan 23, 2025, 7:35 AM EST - 8 months ago

Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

Jan 22, 2025, 4:05 PM EST - 8 months ago

Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025

Jan 21, 2025, 9:15 AM EST - 8 months ago

Leonel Peralta to Join Accuray as Chief Operations Officer

Jan 13, 2025, 3:00 PM EST - 8 months ago

Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System

Jan 7, 2025, 10:52 AM EST - 8 months ago

Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'

Dec 18, 2024, 7:35 AM EST - 9 months ago

New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat

Nov 26, 2024, 4:03 PM EST - 10 months ago

Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

Nov 6, 2024, 10:29 PM EST - 11 months ago

Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 11 months ago

Accuray Reports Fiscal 2025 First Quarter Financial Results

Oct 23, 2024, 4:05 PM EDT - 11 months ago

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Oct 21, 2024, 4:05 PM EDT - 11 months ago

Accuray Appoints Michael Murphy as VP, Corporate Controller

Oct 15, 2024, 8:45 AM EDT - 11 months ago

Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training

Sep 10, 2024, 5:30 PM EDT - 1 year ago

Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution

Sep 3, 2024, 4:10 PM EDT - 1 year ago

Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence

Aug 27, 2024, 7:35 AM EDT - 1 year ago

Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™

Aug 18, 2024, 11:55 AM EDT - 1 year ago

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 14, 2024, 9:02 PM EDT - 1 year ago

Accuray Incorporated (ARAY) Q4 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

Aug 13, 2024, 7:35 AM EDT - 1 year ago

Halifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024

Jun 27, 2024, 7:35 AM EDT - 1 year ago

Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care

Jun 20, 2024, 7:35 AM EDT - 1 year ago

Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients

Jun 12, 2024, 7:35 AM EDT - 1 year ago

Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration

May 22, 2024, 4:30 PM EDT - 1 year ago

Accuray to Participate in the Jefferies Global Healthcare Conference 2024

May 1, 2024, 9:36 PM EDT - 1 year ago

Accuray Incorporated (ARAY) Q3 2024 Earnings Call Transcript

May 1, 2024, 4:06 PM EDT - 1 year ago

Accuray Reports Fiscal 2024 Third Quarter Financial Results

Apr 25, 2024, 7:35 AM EDT - 1 year ago

Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

Apr 18, 2024, 7:35 AM EDT - 1 year ago

Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024

Apr 7, 2024, 12:25 AM EDT - 1 year ago

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Mar 26, 2024, 7:35 AM EDT - 1 year ago

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Mar 4, 2024, 4:30 PM EST - 1 year ago

Accuray Incorporated to Speak at 36th Annual Roth Conference

Feb 27, 2024, 5:30 PM EST - 1 year ago

Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Feb 13, 2024, 7:35 AM EST - 1 year ago

Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System

CaesarZane Sep. 12 at 10:03 AM

$ARAY $HWM $TSLA 👈 Robotics is next!🚀🚀🚀 Full Analysis: https://youtu.be/7a0cvKonwqs

0 · Reply

Tokenist Sep. 8 at 4:37 PM

1 · Reply

DCRMIA Sep. 5 at 5:00 PM

$ARAY Super bullish🚀📈

0 · Reply

d_risk Aug. 28 at 8:25 PM

0 · Reply

MGeronimo Aug. 27 at 6:08 PM

$ARAY accumulating at 1.59

0 · Reply

MSUalum Aug. 26 at 2:32 PM

0 · Reply

OptimistPrime7 Aug. 24 at 1:27 AM

$ARAY One day!

0 · Reply

BreakoutCrafter Aug. 23 at 5:53 AM

$ARAY Accuray Inc is a radiation oncology company facing competitive pressure and slow growth

0 · Reply

StockScanners Aug. 19 at 12:19 AM

$ARAY keep watch if this holds above 1.57

0 · Reply

OkieDokieTrader Aug. 18 at 11:00 PM

$ARAY When they sleep, we eat..? Ok I’m still working on something cool to say. Buy or cry, it’s up to you. Go check my receipts. I call out bangers damn near every day.

0 · Reply

OptimistPrime7 Aug. 18 at 10:58 PM

$ARAY https://finance.yahoo.com/news/investors-undervaluing-accuray-incorporated-nasdaq-130037796.html

0 · Reply

OptimistPrime7 Aug. 18 at 8:01 PM

$ARAY What’s the news I wonder? 15%…

1 · Reply

ZacksResearch Aug. 14 at 5:16 PM

$ARAY shares drop 4.7% post-earnings — what's the story? 📉 Accuray's Q4 EPS missed estimates by 100%, breaking even against the year-ago EPS of 3 cents, while revenues of $127.5M beat by 2.5% despite headwinds in China and EIMEA. Service revenue growth and a solid book-to-bill ratio of 1.2 spotlight areas of resilience. Explore the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2712542/accuray-stock-down-as-q4-earnings-miss-estimates-revenues-down-yy?cid=sm-stocktwits-2-2712542-body-7951&ADID=SYND_STOCKTWITS_TWEET_2_2712542_BODY_7951

0 · Reply

ZacksResearch Aug. 14 at 4:16 PM

$ARAY takes a hit after Q4 miss 📉 Earnings came in below estimates and revenues fell year over year, with product sales pressured by tariffs and softer regional demand. Full breakdown here 👉 https://www.zacks.com/stock/news/2712542/accuray-stock-down-as-q4-earnings-miss-estimates-revenues-down-yy?cid=sm-stocktwits-2-2712542-teaser-7950&ADID=SYND_STOCKTWITS_TWEET_2_2712542_TEASER_7950

0 · Reply

DARKP00L Aug. 14 at 1:34 PM

$ARAY this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

JarvisFlow Aug. 14 at 12:30 PM

BTIG has adjusted their stance on Accuray ( $ARAY ), setting the rating to Buy with a target price of 4 → 5.

0 · Reply

Georges8792 Aug. 14 at 5:22 AM

$ARAY congrats to the new debt holders. They squeeze out all the Ebitda over the next years. Time to get out

0 · Reply

DonCorleone77 Aug. 13 at 8:49 PM

$ARAY Accuray reports Q4 EPS 1c vs. 3c last year -- Q4 revenue $127.5M, consensus $124.47M. -- Sees FY26 revenue $471M-$485M, consensus $445.07M -- Sees FY26 adjusted EBITDA $31M-$35M.

0 · Reply

MGeronimo Aug. 12 at 3:23 PM

$ARAY ADDING PTRE EARNINGS…..

0 · Reply

Estimize Jul. 28 at 11:00 AM

Wall St is expecting 0.01 EPS for $ARAY Q4 [Reporting 08/14 AMC] http://www.estimize.com/intro/aray?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Jul. 18 at 4:34 PM

Is $ARAY positioned for a rebound despite a rocky start? 📈🤔 The Zacks Rank #3 company is banking on strong product demand and a 106.3% projected earnings growth for fiscal 2025, even as it faces tariff challenges and a 31.3% YTD stock slump. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2591932/heres-why-you-should-hold-accuray-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2591932-body-2654&ADID=SYND_STOCKTWITS_TWEET_2_2591932_BODY_2654

0 · Reply

ZacksResearch Jul. 18 at 2:43 PM

$ARAY riding global momentum — but is it enough? CyberKnife demand remains a key tailwind, supporting the bull case, but declining orders and backlog concerns are flashing yellow. Balanced outlook breakdown here 👉 https://www.zacks.com/stock/news/2591932/heres-why-you-should-hold-accuray-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2591932-teaser-2582&ADID=SYND_STOCKTWITS_TWEET_2_2591932_TEASER_2582

1 · Reply

Market Cap	176.90M
Revenue (ttm)	458.51M
Net Income (ttm)	-1.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-0.35%
Debt to Equity Ratio	1.53

Volume	1,542,300
Avg Vol	741,418
Day's Range	N/A - N/A
Shares Out	112.68M
Stochastic %K	58%
Beta	1.26
Analysts	Strong Sell
Price Target	$5.62